% Expired Patents = 75.0

Trademarks = 1

Forward Citations = 1

Loading Chart...

3 inventors (with patents filed for the assignee):

Yitshak Itsik Efrati (3 out of 3 patents)

Peter C Hoyle (1 out of 3 patents)

Paul Waymack (1 out of 2 patents)

4 patents: Sort by Forward Citations

1. 10945960 - Celecoxib and amlodipine formulation and method of making the same (2021-03-16),

2. 10925835 - Celecoxib and amlodipine formulation and method of making the same (2021-02-23),

3. 10350171 - Celecoxib and amlodipine formulation and method of making the same (2019-07-16),

4. 9662315 - Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs (2017-05-30),

Company Overview

Kitov Pharmaceuticals is a clinical-stage company focused on advancing first-in-class oncology drug candidates. Their lead product, NT219, is a novel dual inhibitor that targets key proteins involved in cancer cell survival and resistance. Kitov is dedicated to developing innovative therapies to address unmet medical needs in cancer treatment.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

4 Patents

#264 in Tel Aviv

#1,417 in Israel

Tel Aviv, Israel

Kitov Pharmaceuticals

Forward Citations = 1

3 inventors:

Yitshak Itsik Efrati (3 out of 3 patents)

Peter C Hoyle (1 out of 3 patents)

Paul Waymack (1 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kitov Pharmaceuticals. Retrieved from https://idiyas.com/company/kitov-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]